The Pharmacy Times® Mental Health resource center provides a home where mental health experts and pharmacists can meet to learn about the latest clinical news from the field. With articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content, this is a one-stop shop for folks in both professions.
Hemophagocytic lymphohistiocytosis (HLH) induced by lamotrigine was recently an active topic on social media, with users following a recent article that reported an Austin, Texas detective had died from the condition in 2018.
Megan Maroney, PharmD, BCPP, clinical associate professor, Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey; clinical psychiatric pharmacist, Monmouth Medical Center, Long Branch, NJ, discusses the higher risk for potential adverse effects of suicidal ideation and behavior, and depression in younger patients.
Many individuals with HIV who are receiving antiretroviral therapy have viral genetic material in the cells of their cerebrospinal fluid, making them more likely to experience memory and concentration problems, according to the results of a new study.
In addition to handling issues such as depression, post-traumatic stress disorder, suicide screenings, and anxiety, many mental health pharmacists deal with typical metabolic conditions, such as hypertension and diabetes.
Suicide rates in the United States increased in nearly every state between 1999 and 2016. More than half of the states had a more than 30% rise in suicides during that period. In 2016, nearly 45,000 lives were lost to suicide.
Officials from the FDA have approved Noven Pharmaceuticals, Inc.’s asenapine (Secuado) transdermal system, which is the first-and-only transdermal patch for the treatment of adults with schizophrenia, according to the company.
The Pacific Ketamine Institute is now offering esketamine nasal spray (Spravato, Johnson & Johnson) for the treatment of patients who don't respond well to traditional oral antidepressants. It is a prescription medication to be used alongside an oral antidepressant.1
The FDA has approved Zulresso (brexanolone), from Sage Therapeutics, injection to treat postpartum depression (PPD) in adults.1
The Pharmacy Times® Mental Health specialty page serves as a hub for all clinical news and articles related to mental health conditions, including: anxiety, eating disorders, and, depression. The coverage includes breaking news coverage of therapies recently approved by the US Food and Drug Administration, key takeaways from the latest clinical trials, and notifications of updates to clinical guidelines for countless conditions.